Preclinical evaluation of radiolabelled nimotuzumab, a promising monoclonal antibody targeting the epidermal growth factor receptor
- 30 January 2013
- journal article
- research article
- Published by Wiley in Journal of Labelled Compounds and Radiopharmaceuticals
- Vol. 56 (5), 280-288
- https://doi.org/10.1002/jlcr.2988
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Preparation and preclinical evaluation of 177Lu-nimotuzumab targeting epidermal growth factor receptor overexpressing tumorsNuclear Medicine and Biology, 2012
- Gefitinib Induces Epidermal Growth Factor Receptor Dimers Which Alters the Interaction Characteristics with 125I-EGFPLOS ONE, 2011
- Circumventing the requirement of binding saturation for receptor quantification using interaction kinetic extrapolationNuclear Medicine Communications, 2011
- Preclinical Evaluation of 177Lu-Nimotuzumab: A Potential Tool for Radioimmunotherapy of Epidermal Growth Factor Receptor–Overexpressing TumorsCancer Biotherapy & Radiopharmaceuticals, 2011
- Renal uptake and metabolism of radiopharmaceuticals derived from peptides and proteinsAdvanced Drug Delivery Reviews, 2008
- Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out viewNuclear Medicine and Biology, 2007
- Nimotuzumab: Evidence of Clinical Benefit Without RashThe Oncologist, 2005
- Antiproliferative, antiangiogenic and proapoptotic activity of h‐R3: A humanized anti‐EGFR antibodyInternational Journal of Cancer, 2002
- Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findingsSeminars in Nuclear Medicine, 2002
- The EGFR family and its ligands in human cancerEuropean Journal Of Cancer, 2001